Advances in the preclinical testing of cancer therapeutic hypotheses
The DOI matches its Crossref record; 88 of the 89 references it cites were found in a registry or an index.
Abstract
The genetic and epigenetic underpinnings of cancer are becoming increasingly clear owing to impressive and well-coordinated ventures occurring worldwide. As our understanding of the molecular alterations driving human cancer increases, there is an opportunity to direct the clinical application of cancer therapeutics with improved accuracy. The often empirical treatment of cancer--which was initially based on inhibiting DNA synthesis and cellular division--while having led to a number of remarkable successes, remains prone to a high rate of clinical failure that results partly from a lack of understanding of how best to implement drugs in the clinic. Consequently, it is vital that robust translational strategies be developed preclinically to both reduce failure rates in the clinic and shorten the time required to identify patient populations most likely to benefit from a given therapeutic. Here, we review both historical and current uses of preclinical model systems, being mindful that a combination of approaches will be needed to address all meritorious therapeutic hypotheses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Such mutations were initially identified through the study of samples taken from patients with relapsed diseas”
BackgroundOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“, as well as a variety of lesions in oncogenic driver genes including KRAS , epidermal growth factor receptor ( EGFR ), phosphoinositide 3-kinase, catalytic, alpha polypeptide (PI3KCA) and anaplastic lymphoma receptor tyrosine kinase (ALK), among other”
BackgroundThe NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299
Research works printed but not linked: 2
- Fantini, A., Moser, L., Partridge, R. & Halliday, J. L. The effect of actinomycin D on several mouse tumors. Proc. Am. Assoc. Cancer Res. 2, 108 (1956).
- Farber, S. Carcinolytic action of antibiotics: puromycin and actinomycin D. Am. J. Pathol. 31, 582 (1955).
Cited by
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationDrost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
“…xenografts have been used extensively and when selected to exhibit the relevant molecular characteristics and pathogenic drivers can mimic many of the features and response to targeted drugs of the corresponding human cancers (Caponigro and Sellers, 2011; Ocana et al., 2011; Workman et al., 2010).”
BackgroundInfluentialPharmacogenomic agreement between two cancer cell line data sets
The Cancer Cell Line Encyclopedia Consortium, & The Genomics of Drug Sensitivity in Cancer Consortium (2015) · Nature · doi:10.1038/nature15736 · Cited by 418
Organoid cultures for the analysis of cancer phenotypes
Sachs, N., & Clevers, H. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.012 · Cited by 371
“a The following three general classes of anti-cancer drugs have been established for judging the use of preclinical models: agents targeting tumorspecific proteins, agents targeting host-tumor interactions, and agents targeting tumor cells empirically [3].”
BackgroundInfluentialOrganoid technology and applications in cancer research
Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0662-9 · Cited by 345
“For most cytotoxic agents, broad activity was observed across tumor cell lines, but clinical efficiency noted in patients was in more limited settings [93].”
BackgroundCancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.652 · Cited by 306
“Obviously some genes can fall into multiple classifications [11].”
Modeling neoplastic disease with spheroids and organoids
Zanoni, M., Cortesi, M., Zamagni, A., Arienti, C., Pignatta, S., & Tesei, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00931-0 · Cited by 261
Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient
Caballero, D., Kaushik, S., Correlo, V. M., Oliveira, J. M., Reis, R. L., & Kundu, S. C. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.005 · Cited by 221
Zhou, Z., Cong, L., & Cong, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.762184 · Cited by 178
“This contributes to the low success rate of newly developed drugs in clinical trials (5, 6).”
BackgroundImaging preclinical tumour models: improving translational power
de Jong, M., Essers, J., & van Weerden, W. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3751 · Cited by 176
Computational models for predicting drug responses in cancer research
Azuaje, F. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw065 · Cited by 59
A review of microfluidic approaches for investigating cancer extravasation during metastasis
Ma, Y.-H. V., Middleton, K., You, L., & Sun, Y. (2018) · Microsystems & Nanoengineering · doi:10.1038/micronano.2017.104 · Cited by 154
New Insights into Toxicity and Drug Testing
(2013) · InTech eBooks · doi:10.5772/55886 · Cited by 149
“[86] Froscio SM, Cannon E, Lau HM, Humpage AR.”
BackgroundInfluentialLu, S., Cuzzucoli, F., Jiang, J., Liang, L.-G., Wang, Y., Kong, M., Zhao, X., Cui, W., Li, J., & Wang, S. (2018) · Lab on a Chip · doi:10.1039/c8lc00852c · Cited by 144
Vougas, K. N., Sakellaropoulos, T., Kotsinas, A., Foukas, G.-R. P., Ntargaras, A., Koinis, F., Polyzos, A., Myrianthopoulos, V., Zhou, H., Narang, S., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107395 · Cited by 138
Animal-derived products in science and current alternatives
Duarte, A. C., Costa, E. C., Filipe, H. A. L., Saraiva, S. M., Jacinto, T., Miguel, S. P., Ribeiro, M. P., & Coutinho, P. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213428 · Cited by 117
Li, H., Wawrose, J. S., Gooding, W. E., Garraway, L. A., Lui, V. W. Y., Peyser, N. D., & Grandis, J. R. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0396 · Cited by 125
“In 2010, the genomic profiling and pharmacologic data for 311 cancer cell lines was released by GlaxoSmithKline via the National Cancer Institute's cancer BioinformaticsGrid (caBIG), including 10 HNSCC cell lines (7).”
MethodFunctional exploration of colorectal cancer genomes using Drosophila
Bangi, E., Murgia, C., Teague, A., Sansom, O. J., & Cagan, R. L. (2016) · Nature Communications · doi:10.1038/ncomms13615 · Cited by 117
HSP90 inhibition: two-pronged exploitation of cancer dependencies
Travers, J., Sharp, S. Y., & Workman, P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.021 · Cited by 110
Wang, Y., Wu, D., Wu, G., Wu, J., Lu, S., Lo, J., He, Y., Zhao, C., Zhao, X., Zhang, H., et al. (2020) · Theranostics · doi:10.7150/thno.38736 · Cited by 93
“On the other hand, animal models for drug testing are labor/time intensive, costly, and most importantly, often yield untranslatable results due to the physiological differences between humans and animal models [11-14].”
BackgroundDeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration
Wang, Y., Yang, Y., Chen, S., & Wang, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab048 · Cited by 94
Lim, J., Ching, H., Yoon, J., Jeon, N. L., & Kim, Y. (2021) · Nano Convergence · doi:10.1186/s40580-021-00261-y · Cited by 91
An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines
Dutil, J., Chen, Z., Monteiro, Á. N. A., Teer, J. K., & Eschrich, S. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2747 · Cited by 76
“However, in the era of precision medicine, 60 cell lines represents only a small number of the over 100 histologies of cancer (79).”
BackgroundOrganoid models in lung regeneration and cancer
Wang, J., Li, X., & Chen, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.030 · Cited by 68
Comparison and validation of genomic predictors for anticancer drug sensitivity
Papillon-Cavanagh, S., De Jay, N., Hachem, N., Olsen, C., Bontempi, G., Aerts, H. J. W. L., Quackenbush, J., & Haibe-Kains, B. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001442 · Cited by 65
A 3D Biomimetic Model of Tissue Stiffness Interface for Cancer Drug Testing
Lam, C. R. I., Wong, H. K., Nai, S., Chua, C. K., Tan, N. S., & Tan, L. P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500059q · Cited by 63
Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back
Yadav, A. K., Srikrishna, S., & Gupta, S. C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.010 · Cited by 62
Organoid models of the tumor microenvironment and their applications
Xia, T., Du, W., Chen, X., & Zhang, Y.-N. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16578 · Cited by 66
Bousquet, G., Bouchtaoui, M. E., Tan, S., Lebœuf, C., de BAZELAIRE, C., Ratajczak, P., Giacchetti, S., de Roquancourt, A., Bertheau, P., Verneuil, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16925 · Cited by 66
Tumor organoids: From inception to future in cancer research
Yang, L., Yang, S., Li, X., Li, B., Li, Y., Zhang, X., Ma, Y., Peng, X., Jin, H., Fan, Q., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.005 · Cited by 64
Miniaturized Three-Dimensional Cancer Model for Drug Evaluation
Lovitt, C. J., Shelper, T., & Avery, V. M. (2013) · Assay and Drug Development Technologies · doi:10.1089/adt.2012.483 · Cited by 61
“13 Despite our understanding of many cancers, and their molecular biology becoming increasingly clear, the number of drugs failing clinical trials remains high.”
Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
Mer, A. S., Ba-Alawi, W., Smirnov, P., Wang, Y. X., Brew, B., Ortmann, J., Tsao, M.-S., Cescon, D. W., Goldenberg, A., & Haibe-Kains, B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0349 · Cited by 59
Orthotopic models of pediatric brain tumors in zebrafish
Eden, C., Ju, B. H., Murugesan, M., Phoenix, T. N., Nimmervoll, B. V., Tong, Y., Ellison, D. W., Finkelstein, D., Wright, K. D., Boulos, N., et al. (2014) · Oncogene · doi:10.1038/onc.2014.107 · Cited by 58
Organoid of ovarian cancer: genomic analysis and drug screening
Liu, H., Xia, B., Jin, M., & Lou, G. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02276-8 · Cited by 61
Shu, D., Shen, M., Li, K., Han, X., Li, H., Tan, Z., Wang, Y., Peng, Y., Tang, Z., Qu, C., et al. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2122550 · Cited by 62
“This complication mainly arises to the failure of many cancer models to recapitulate patient tumours [12]; therefore, many drugs that perform well in cancer models eventually fail in clinical trials [13].”
BackgroundHoneycomb-Like Hydrogel Microspheres for 3D Bulk Construction of Tumor Models
He, J., Chen, C., Chen, L., Cheng, R., Sun, J., Liu, X., Wang, L., Zhu, C., Hu, S., Xue, Y., et al. (2022) · Research · doi:10.34133/2022/9809763 · Cited by 63
“At present, research on the tumorigenic mechanism and drug screening mainly rely on the tumor cells cultured on the two-dimensional (2D) plate [2].”
BackgroundGastrointestinal cancer organoids—applications in basic and translational cancer research
Seidlitz, T., & Stange, D. E. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00654-3 · Cited by 58
Rahavendran, S. V., Vekich, S., Skor, H. E., Batugo, M. R., Nguyen, L., Shetty, B. V., & Shen, Z. (2012) · Bioanalysis · doi:10.4155/bio.12.85 · Cited by 47
Microfluidics for Cancer Nanomedicine: From Fabrication to Evaluation
Zhang, H., Zhu, Y., & Shen, Y. (2018) · Small · doi:10.1002/smll.201800360 · Cited by 49
Liabeuf, D., Oshima, M., Stange, D. E., & Sigal, M. J. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.12.252 · Cited by 49
Applications of lung cancer organoids in precision medicine: from bench to bedside
Li, H., Chen, Z., Chen, N., Fan, Y., Xu, Y., & Xu, X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01332-9 · Cited by 52
“In the past, the development and screening of many anti-neoplastic agents was performed using standard cell lines, but they proved ineffective in clinical studies [59].”
BackgroundDeepDRA: Drug repurposing using multi-omics data integration with autoencoders
Mohammadzadeh-Vardin, T., Ghareyazi, A., Gharizadeh, A., Abbasi, K., & Rabiee, H. R. (2024) · PLOS ONE · doi:10.1371/journal.pone.0307649 · Cited by 40
Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy
Wu, W., Li, X., & Yu, S. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.04.050 · Cited by 42
Somatic variation and cancer: therapies lost in the mix
Biankin, A. V., & Hudson, T. J. (2011) · Human Genetics · doi:10.1007/s00439-011-1010-0 · Cited by 39
“Pre-clinical models may prove to be beneficial in resolving some of these issues more efficiently (Caponigro and Sellers 2011), and an article addresses this strategy later in this issue (Pajic et al.”
BackgroundTargeting cancer drug resistance utilizing organoid technology
Chai, C., Ji, P., Xu, H., Tang, H., Wang, Z., Zhang, H., & Zhou, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114098 · Cited by 38
Dzobo, K., Rowe, A., Senthebane, D. A., AlMazyadi, M., Patten, V. A., & Parker, M. I. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0172 · Cited by 38
“Moreover, candidate drugs that are effective in vitro or animal cancer models tend to fail miserably during clinical trials (Caponigro and Sellers, 2011; Choi et al., 2014; Ruggeri et al., 2014).”
Farhat, J., Pandey, I., & Alwahsh, M. (2021) · Cells · doi:10.3390/cells10071657 · Cited by 36
“Despite this remarkable progress, cancer-related tumor characteristics [14], disease progression as well as the mechanism of action of a newly discovered drug [15] or even the modification of an old drug [11] characteristics in order to improve patient’s quality of life [16], adherence, compliance, and death rates are…”
BackgroundGreek, R., & Hansen, L. A. (2013) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2013.06.002 · Cited by 36
Integration of organoids in peptide drug discovery: Rise of the high‐throughput screening
Zhang, S., Shen, J., Wang, X., Sun, X., Wu, Y., Zhang, M., Wang, R., & Hu, K. (2023) · View · doi:10.1002/viw.20230010 · Cited by 34
The third dimension: new developments in cell culture models for colorectal research
Pereira, J., Awatade, N. T., Loureiro, C. A., Matos, P., Amaral, M. D., & Jordan, P. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2258-2 · Cited by 36
“Indeed, many promising candidate drugs to treat cancer perform well in preclinical cell line models but later fail to deliver a clinical response in animal or patient trials [58, 129].”
BackgroundKalot, R., Mhanna, R., & Talhouk, R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108156 · Cited by 31
Animal Models in an Age of Personalized Medicine
Greek, R., Menache, A., & Rice, M. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.89 · Cited by 32
Zheng, Q., Zhang, B., Li, C., & Zhang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.850732 · Cited by 35
“Despite that great efforts have been devoted to developing new targeted therapies based on positive results generated from cell line experiment models, it is pitiful that few compounds go beyond preclinical study, which may be mainly attributed to failing to recapitulate the multiple features of the tumor of the patie…”
BackgroundPatient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease
Bousquet, G., & Janin, A. (2016) · Pathobiology · doi:10.1159/000444533 · Cited by 35
Wang, W., Yang, Z., Xiao, X., An, T., Li, B., Ouyang, J., Li, H., Wang, C., Zhang, Y., Zhang, H., et al. (2020) · Journal of Cancer · doi:10.7150/jca.40744 · Cited by 29
Patient-derived organoids: a promising tool for breast cancer research
Shi, Y., Guan, Z., Cai, G., Nie, Y., Zhang, C., Luo, W., & Liu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1350935 · Cited by 32
“For example, in a previous study, only seven prostate cancer cell lines were generated, with only four expressing androgen receptors (33).”
BackgroundCancer drug discovery: recent innovative approaches to tumor modeling
Lovitt, C. J., Shelper, T., & Avery, V. M. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1214562 · Cited by 31
“Although monoculture models based on a single cancer cell line can provide large amounts of data in drug discovery programs, models based on a single cell type still poorly represent complex tumor physiology [26].”
BackgroundOrganotypic Models for Functional Drug Testing of Human Cancers
Huang, Y. L., Dickerson, L. K., Kenerson, H. L., Jiang, X., Pillarisetty, V. G., Tian, Q., Hood, L., Gujral, T. S., & Yeung, R. S. W. (2023) · BME Frontiers · doi:10.34133/bmef.0022 · Cited by 29
“First and foremost, there often exists incongruity between preclinical models and the human cancers of interest, thus the screening platforms are poor surrogates of patient tumors [2,3].”
BackgroundDrug resistance profiling of a new triple negative breast cancer patient-derived xenograft model
Matossian, M. D., Burks, H. E., Elliott, S. G., Hoang, V. T., Bowles, A. C., Sabol, R. A., Wahba, B., Anbalagan, M., Rowan, B. G., Abazeed, M. E., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5401-2 · Cited by 28
“Clinical trials with targeted inhibitors in oncology have high failure rates [1, 2]; in fact, only 7.”
BackgroundBousquet, G., Feugeas, J., Gu, Y., Lebœuf, C., Bouchtaoui, M. E., Lu, H., Espié, M., Janin, A., & Benedetto, M. D. (2019) · Oncotarget · doi:10.18632/oncotarget.27312 · Cited by 25
“One major explanation is that their durable in vitro development results from genetic stress and changes that do not reflect the carcinogenesis process in a patient [17].”
BackgroundChen, J., & Na, F. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1066869 · Cited by 27
“1 Drug testing During the past decades, scientists have used the traditional 2D culture cell lines to screen antitumor drugs, most of which have proved ineffective in clinical studies (Caponigro and Sellers, 2011).”
BackgroundSpecific metabolic response of patient-derived organoids to curcumin of colorectal cancer
Chen, L., Dai, Z., Ge, C., Huang, D., Zhou, X., Pan, K., Xu, W., Fu, J., & Du, J. L. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123260 · Cited by 27
Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer
Urbaniak, A. J., Reed, M. R., Heflin, B., Gaydos, J., Piña‐Oviedo, S., Jędrzejczyk, M., Klejborowska, G., Stępczyńska, N., Chambers, T. C., Tackett, A. J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113440 · Cited by 28
Screening for Anti‐cancer Drugs in Drosophila
Richardson, H. E., Willoughby, L. F., & Humbert, P. O. (2015) · Wiley eBooks · doi:10.1002/9780470015902.a0022535 · Cited by 26
Workman, P. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2612 · Cited by 24
The impact of molecular targets in cancer drug development: major hurdles and future strategies
Hebar, A., Valent, P., & Selzer, E. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.71 · Cited by 27
Animal Models in Drug Development
Greek, R. (2013) · InTech eBooks · doi:10.5772/53893 · Cited by 23
“Profound inter-species differences, as well as inter-indi‐ vidual human differences, have been revealed for absorption [[59] p 8-10] [[60] pp 5, 9, 45, 50, 66-7, 90, 102-3,] [61-64], distribution [65, 66], metabolism [67-77], elimination [78, 79], and toxicity [64, 80-91], which results in predictive values for these…”
BackgroundNovel organoid model in drug screening: Past, present, and future
Nie, X., Liang, Z., Li, K., Yu, H., Huang, Y., Ye, L., & Yang, Y. (2021) · Liver Research · doi:10.1016/j.livres.2021.05.003 · Cited by 23
Selected Topics in Plastic Reconstructive Surgery
Danilla, S. (2012) · InTech eBooks · doi:10.5772/1292 · Cited by 22
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia
McCormack, E., Mujić, M., Osdal, T., Bruserud, Ø., & Gjertsen, B. T. (2012) · Blood · doi:10.1182/blood-2012-05-429555 · Cited by 20
The potential application of organoids in breast cancer research and treatment
Ebrahimi, N., Esfahani, A. N., Samizade, S., Mansouri, A., Ghanaatian, M., Adelian, S., Shadman-Manesh, V., & Hamblin, M. R. (2021) · Human Genetics · doi:10.1007/s00439-021-02390-0 · Cited by 22
Rational design matrix materials for organoid development and application in biomedicine
Huang, Y. F., Zhang, X., Zhang, W., Tang, J., & Liu, J. (2025) · Regenerative Biomaterials · doi:10.1093/rb/rbaf038 · Cited by 23
“…cancer models, such as 2D cancer cell lines, genetically engineered mouse models and primary patient-derived xenograft (PDXs), have poor reproducibility for human tumors, which has led to unsatisfactory results in clinical trials of drugs that work well in traditional cancer models [140, 141].”
In vitro clinical trials: the future of cell-based profiling
Ross, N. T., & Wilson, C. J. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00121 · Cited by 20
“There are several good reviews on the development of these large scale cancer cell panels (Shoemaker, 2006; Sharma et al., 2010; Caponigro and Sellers, 2011) and their application to patient selection and pharmacological compound analysis.”
BackgroundStem Cell Based Preclinical Drug Development and Toxicity Prediction
Kumar, D., Baligar, P., Srivastav, R., Narad, P., Raj, S., Tandon, C., & Tandon, S. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201019104712 · Cited by 21
Williams, R. J., Walker, I., & Takle, A. K. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.01.020 · Cited by 18
Personalized Medicine: Patient-Predictive Panel Power
Workman, P., Clarke, P. A., & Al‐Lazikani, B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.030 · Cited by 16
“However, it became clear that hundreds of cancer cell lines must now be used to mimic clinical heterogeneity and to account for pathogenic driver mutations present in only, say, 5% or even less of cancers (Caponigro and Sellers, 2011; Garnett and McDermott, 2012).”
BackgroundTumor xenograft modeling identifies TCF4/ITF2 loss associated with breast cancer chemoresistance
Ponce, G. R. D. G., Mateo, F., Stradella, A., Valdés‐Mas, R., Palomero, L., Serra-Musach, J., Puente, D. A., Díaz‐Navarro, A., Vargas‐Parra, G., Tornero, E., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.032292 · Cited by 16
“Nevertheless, chemotherapy is generally applied empirically, with no validated test or biomarker to reliably predict response to or benefit from a particular regime (Caponigro and Sellers, 2011).”
Jurj, A. M., Paşca, S., Braicu, C., Rusu, I., Korban, S. S., & Berindan‐Neagoe, I. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.002 · Cited by 17
Advances of Patient-Derived Organoids in Personalized Radiotherapy
Wang, Y., Li, Y., Sheng, Z., Deng, W., Yuan, H., Wang, S., & Liu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.888416 · Cited by 21
“Many anticancer therapeutics performing excellently in vitro and in vivo at the lab have failed in clinical trials (3).”
BackgroundMonleón-Guinot, I., Milián, L., Martínez-Vallejo, P., Sancho‐Tello, M., Llop-Miguel, M., Galbis, J. M., Cremades, A., Cardá, C., & Mata, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210131 · Cited by 15
A Review of the Institute of Medicine’s Analysis of using Chimpanzees in Biomedical Research
Jones, R. C., & Greek, R. (2013) · Science and Engineering Ethics · doi:10.1007/s11948-013-9442-7 · Cited by 15
Prediction of cancer drug sensitivity using high-dimensional omic features
Chen, T.-H., & Sun, W. (2016) · Biostatistics · doi:10.1093/biostatistics/kxw022 · Cited by 14
“For permissions, please e-mail: journals.permissions@oup.com. such as cancer cell lines that reflect the genomic diversity of human cancers can be used to identify predictive omic features/biomarkers for drug sensitivity (Caponigro and Sellers, 2011).”
BackgroundZheng, S., Zhou, Z., Ji, J., Liu, Y., Jiao, X., Li, X., Shen, Y., Hong, H., & Han, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113862 · Cited by 17
Zhang, Y., Lu, A., Zhuang, Z., Zhang, S., Liu, S., Chen, H., Yang, X., & Wang, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s424737 · Cited by 14
“This is largely due to inappropriate modeling of tumors, as these models cannot recapitulate pathogenic processes in patients.(11) Organoids, defined as “a collection of organ-specific cell types that develops from stem cells or organ progenitors and self-organizes through cell sorting and spatially restricted lineage…”
BackgroundQu, B., Mu, Q., Bi, H., Chen, Y., Wang, Q., Ma, X., & Lu, L. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1433111 · Cited by 13
An analysis of the Bateson Review of research using nonhuman primates
Greek, R., Hansen, & Menache (2011) · Medicolegal and Bioethics · doi:10.2147/mb.s25938 · Cited by 15
Advantages of the avian model for human ovarian cancer
Bernardo, A. D. M., Þorsteinsdóttir, S., & Mummery, C. L. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.619 · Cited by 14
Sensor-free and Sensor-based Heart-on-a-chip Platform: A Review of Design and Applications
Wan, H., Gu, C., Gan, Y., Wei, X., Zhu, K., Hu, N., & Wang, P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190207170004 · Cited by 13
Liver Buds and Liver Organoids: New Tools for Liver Development, Disease and Medical Application
Zeng, F., Zhang, Y., Han, X., Weng, J., & Gao, Y. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09909-z · Cited by 13
“As a result, many drugs that perform effectively in animal models but fail in clinical trials [74].”
BackgroundDrugs for solid cancer the productivity crisis prompts a rethink
Brábek, J., Rösel, Veselý, P., & Fernandes, M. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s45177 · Cited by 13
Integrative microphysiological tissue systems of cancer metastasis to the liver
Clark, A. M., Allbritton, N. L., & Wells, A. H. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.010 · Cited by 12
The Fibrotic Phenotype of Human Precision-Cut Lung Slices Is Maintained after Cryopreservation
Marimoutou, M., Patel, V., Kim, J. H., Schaible, N., Alvarez, J., Hughes, J., Obermok, M., Rodríguez, C. I., Kallarakkal, T. G., Suki, B., et al. (2024) · Toxics · doi:10.3390/toxics12090637 · Cited by 12
Associating lncRNAs with small molecules via bilevel optimization reveals cancer-related lncRNAs
Wang, Y., Chen, S., Chen, L., & Wang, Y. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007540 · Cited by 11
“Jointly, these valuable data hint the mechanism of action of drugs in cancer [32, 33].”
BackgroundOrganoids derived from metastatic cancers: Present and future
Zheng, X., Zhang, X., & Yu, S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30457 · Cited by 11
“Over the past few decades, many drugs that are expected to be effective in theory and that have performed well in cancer models have ultimately failed in clinical trials [7].”
BackgroundRodríguez, D. A. S., Ramos‐Murillo, A. I., & Godoy‐Silva, R. D. (2021) · Bioprinting · doi:10.1016/j.bprint.2021.e00171 · Cited by 10
Patient-derived organoids in ovarian cancer: Current research and its clinical relevance
Kumar, S., Raina, M., Tankay, K., & Ingle, G. M. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115589 · Cited by 12
Metadata
- Authors
- Caponigro, G., & Sellers, W. R.
- Corresponding author
- Caponigro, Giordano
- ORCID
- Sellers, William R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-03
- Volume
- 10
- Issue
- 3
- Pages
- 179-187
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2091336659
- Cited by
- 165
- References
- 89
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 8 · 2023: 11 · 2022: 14 · 2021: 18 · 2020: 10 · 2019: 15 · 2018: 7 · 2017: 4 · 2016: 16 · 2015: 6 · 2014: 10 · 2013: 12 · 2012: 14
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Institutes for BioMedical Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- preclinical cancer models, translational oncology, anticancer drug development, drug attrition, clinical trial failure, patient selection
- MeSH terms
- Animals, Antineoplastic Agents, Disease Models, Animal, Drug Evaluation, Preclinical, Genetic Engineering, Humans, Models, Biological, Neoplasms, Cell Line, Tumor, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.